Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pricing Strategies

Set Alert for Pricing Strategies

Germany’s Pro Generika Sees Steep Revlimid Savings

Generic lenalidomide competitors to BMS’ Revlimid brand have brought the cost of the cancer drug down by as much as 60% in Germany just a couple of months after launch, according to local generics association Pro Generika. However, the industry body has warned, price pressure must not grow so pronounced that the generics market becomes unsustainable.

Generic Drugs Pricing Strategies

Inflation Impact Must Be Considered During Generics Pricing, Says Canadian Study

Canadian provinces must consider the impact of inflation on generic drugs during the next round of off-patent price setting, says a study from Aviseo and the Canadian Generic Pharmaceutical Association.

Generic Drugs Pricing Strategies

Teva: Payers Hold The Cards On Material 2023 Adalimumab Opportunity

Fresh from partner Alvotech resolving patent litigation in the US for its proposed Humira biosimilar, Teva management has detailed the firm’s expectations around the product and the crucial issue of supply.

Biosimilars Reimbursement

Solifenacin Surges As UK Sees Huge Price Rises In April

Multiple different generics saw triple-digit-percentage price rises that led UK averages to as much as quadruple in April 2022, according to the latest figures from WaveData. Solifenacin and ibandronic acid led the month’s steepest increases.

Market Intelligence Pricing Strategies

Generics Industry Braces For New Wave Of Price Pressure

With pricing pressures already creeping up in recent years, 2022 is set to see the generics industry caught in the middle as prices are further squeezed while costs continue to rise. As major players prepare to announce their first-quarter financial results, Generics Bulletin looks at views from industry leaders on how these pressures are affecting their businesses, and how they can be expected to play out.

Pricing Strategies Sales & Earnings

UK Pramipexole Prices Plummet In March

Multiple presentations of pramipexole modified-release tablets saw their average UK trade prices nosedive in March, according to the latest figures from market researcher WaveData, which also revealed the reason for the dramatic declines.

Market Intelligence Pricing Strategies

Celltrion Launches Higher-Strength Yuflyma Adalimumab In Canada

Months after it received approval from local regulator Health Canada, Celltrion’s Yuflyma high-concentration adalimumab biosimilar is now available in the North American market, setting up a potential rivalry with Alvotech and its marketing partner JAMP Pharma.

Launches Reimbursement

Coherus Identifies Stealing Amgen’s Crown As Pegfilgrastim Market Leader

With its Udenyca pegfilgrastim biosimilar sales plunging in 2021 amid pricing and volume pressures, Coherus is looking to balance price and share trade-offs in 2022 before the intended launch of its proposed on-body injector device next year – in turn aiming to become the eventual pegfilgrastim market leader.

Advertising, Marketing & Sales Biosimilars

Generics Bulletin Editor’s Picks For Q1 2022

Looking back over the first quarter of 2022, Generics Bulletin executive editor David Wallace picks out highlights from January to March that include a number of major deals in the biosimilars sector, warnings of increasing price pressure on generics, and key strategy updates from companies across the off-patent sector.

Biosimilars Generic Drugs
See All
UsernamePublicRestriction

Register